OBJECTIVES The monoamine oxidase B inhibitors selegiline and rasagiline have not been compared in head-to-head clinical trials in patients with early Parkinson's disease.  The aim of this review was to compare the efficacy of these two agents in this setting. MATERIALS AND METHODS Randomized, placebo-controlled trials with an endpoint of the mean change from baseline in the Unified Parkinson'...

Selegiline is best known as an irreversible inhibitor of monoamine oxidase (MAO), an intracellular enzyme associated with the outer membrane of mitochondria. The purpose of this study is to establish a reliable and quick method for the assignment of selegiline in human plasma by high performance liquid chromatography with ultraviolet detection. A rapid and sensitive high performance liquid chro...

Parkinson disease is characterized by the death of dopaminergic neurons in the substantia nigra pars compacta. We explored the neuroprotective effect of Selegiline and Piribedil, the Monoamine Oxidase Type B (MAO-B) and dopamine agonist to Parkinson disease (PD). After embryonic Wistar rat were induced by cerebrospinal fluid (CSF) from PD patients, Selegiline and Piribedil were administered to ...

Study selection Studies were selected if they were unconfounded, double blind, randomised controlled trials that compared selegiline with placebo in patients with Alzheimer’s disease. Studies had to have been reported before the end of 1998; patients had to meet NINCDSADRDA or DSM criteria for Alzheimer’s disease; and any secondary treatments (eg, physostigmine and lecithin) had to be given to ...

It has been suggested that in patients with Parkinson’s disease (PD) metabolism of the MAO-B inhibitor selegiline to methamphetamine may contribute and/or exacerbate sleep problems, possibly leading to deficits of cognition. This open-label exploratory study included 30 PD patients currently being treated with selegiline (7.5 mg/day) and complaining of sleep disturbances. The aim of the study w...